• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Egyptian Journal of Medical Human Genetics >Impact of PAI-1 4G/5G and C??G polymorphisms in acute ST elevation myocardial infarction and stable angina patients: A single center Egyptian study
【24h】

Impact of PAI-1 4G/5G and C??G polymorphisms in acute ST elevation myocardial infarction and stable angina patients: A single center Egyptian study

机译：PAI-1 4G / 5G和C？>？G多态性对急性ST段抬高型心肌梗塞和稳定型心绞痛患者的影响：单中心埃及研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Many genetic factors, including polymorphisms in the genes regulating blood coagulation and fibrinolysis have been proposed as risk factors for coronary artery disease (CAD). PAI-1 is the chief inhibitor of tissue plasminogen activator and urokinase plasminogen activator. PAI-1 has a crucial role in regulation of fibrinolysis. Aim of the study Is to investigate the association between Plasminogen activator inhibitor-1 (PAI-1) 4G/5G, PAI-1C/G polymorphisms and CAD. In addition, studying the relation of these polymorphisms to the level of active PAI-1 in Egyptian patients presenting to a single tertiary center in Cairo. Subjects and methods One hundred and forty-four patients were included in this study: 42 STEMI (ST elevation myocardial infarction) patients, 63 stable angina patients, and 39 as a control group. Detection of PAI-1 4G/5G and C?>?G polymorphisms was done using allele specific polymerase chain reaction and restriction fragment length polymorphism (RFLP) respectively. Plasma plasminogen activator inhibitor-1 activity was detected using enzyme linked immunosorbent assay (ELISA). Results In the studied CAD patients, PAI-14G/5G polymorphism showed 31.7%, and 68.3% for 5G/5G, and (4G/5G?+?4G/4G) respectively; however for the control group, 5G/5G, and (4G/5G?+?4G/4G) were detected in 21.6%, and 78.4% respectively (p value 0.59). The genotypic frequencies for PAI-1C/G in CAD patients accounted for 27% (CC), 73% (CG?+?GG); while in the control group these frequencies were 35.3%, and 64.7% respectively (p value 1.43). Conclusion No significant association between PAI-1 4G/5G and C?>?G polymorphisms and the risk of coronary artery disease or the activity level of PAI-1 among the studied Egyptian population sample. However, STEMI patients showed significant presence of combined mutant allele of both genes more frequently.
机译：背景技术已提出许多遗传因素，包括调节血液凝固和纤维蛋白溶解的基因中的多态性，作为冠心病（CAD）的危险因素。 PAI-1是组织纤溶酶原激活物和尿激酶纤溶酶原激活物的主要抑制剂。 PAI-1在调节纤维蛋白溶解中起关键作用。该研究的目的是研究纤溶酶原激活物抑制剂1（PAI-1）4G / 5G，PAI-1C / G多态性与CAD之间的关系。此外，研究了在开罗一个三级中心就诊的埃及患者中这些多态性与活性PAI-1水平的关系。对象和方法本研究共纳入144例患者：42例STEMI（ST抬高型心肌梗塞）患者，63例稳定型心绞痛患者和39例作为对照组。分别使用等位基因特异性聚合酶链反应和限制性片段长度多态性（RFLP）检测PAI-1 4G / 5G和C1＞ΔG多态性。使用酶联免疫吸附测定（ELISA）检测血浆纤溶酶原激活物抑制剂1的活性。结果在研究的CAD患者中，PAI-14G / 5G多态性分别为5G / 5G和（4G / 5G→+ 4G / 4G），分别为31.7％和68.3％。但是，对照组中分别检测到21.6％和78.4％的5G / 5G和（4G /5Gβ+Δ4G/ 4G）（p值0.59）。 CAD患者中PAI-1C / G的基因型频率占27％（CC），73％（CGα+ΔGG）。而对照组的这些频率分别为35.3％和64.7％（p值1.43）。结论在埃及研究人群中，PAI-1 4G / 5G和C1>ΔG多态性与冠心病风险或PAI-1活性水平之间无显着相关性。但是，STEMI患者更频繁地显示两种基因的组合突变等位基因的显着存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号